Lens Diseases: Clinical Trials

161 trials for Lens Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

117 completed, 17 unknown, 9 terminated, 8 withdrawn. 161 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4161Completed 117, Unknown 17, Terminated 9, Withdrawn 8, Recruiting 5, Not yet recruiting 4, Active not recruiting 1

Follow Lens Diseases: new trials by email Literature Review of Lens Diseases trials Research Report on Lens Diseases

Trials (filtered) newest first · largest first

All 161 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Evaluation of Visual Performance, Spectacle Independence, and Patient Satisfaction With TECNIS PureSee Mini-Monovision and TECNIS PureSee-TECNIS Odyssey Mix-Match
TECNIS PureSee IOL (Model DEN00V/DET150), TECNIS Odyssey IOL (Model DRN00V/DRT150) - Presbyopia Correction, Presbyopia
Phase 4Not yet recruitingDr. Daniel H. Chang, MD682026-10-012026-10-06
A Prospective, Single-Arm Clinical Evaluation of Visual, Refractive, and Patient-Reported Outcomes Following Bilateral Implantation of the TECNIS PureSee™ Extended Depth of Focus Intraocular Lens
PureSee IOL - Cataract
Phase 4Not yet recruitingVance Thompson Vision502026-09-012026-08-27
Toric Performance And Constant Evaluation
Monofocal toric IOL - Cataract
Phase 4RecruitingCarl Zeiss Meditec AG1302026-07-132026-07-22
A Prospective, Randomized, Subject- and Examiner-Masked, Multicenter Study Comparing Bilateral Clareon TruPlus and Bilateral Clareon Monofocal Intraocular Lens Implantation (Spherical and Toric) in Cataract Subjects
Clareon TruPlus, Clareon monofocal - Cataract
Phase 4RecruitingBerkeley Eye Center1802026-06-122026-07-21
Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery
Rebamipide 2% ophthalmic solution, Diquafosol 3% ophthalmic solution - Dry Eye Disease (DED), Cataract
Phase 4Not yet recruitingSamsung Medical Center602026-03-012026-02-09
Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery
Aflibercept (Eylea) - Diabetic Retinopathy (DR), Diabetic Macular Edema (DME)
Phase 4Not yet recruitingAhmad Zeeshan Jamil1662026-01-012025-12-24
Odyssey Evaluation in Post LASIK Patients
Odyssey intraocular lens - Cataract
Phase 4Active not recruitingCenter For Sight302025-08-182026-10-26
Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery
Rebamipide 2% ophthalmic solution, Diquafosol 3% ophthalmic solution, Cyclosporine 0.05% ophthalmic solution - Dry Eye Disease (DED), Cataract
Phase 4CompletedSamsung Medical Center562025-08-012026-10-27
Assessment of CataClear, Tear Film Stability, Tear Volume, and Dry Eye Symptoms Using Stem Cells Fortified Eye Drops
eye drops - Dry Eye, Cataract
Phase 4RecruitingAce Cells Lab Limited3002025-04-222025-09-25
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
Clareon PanOptix, Clareon PanOptix PRO, Mix-and-Match PanOptix/Vivity - Cataract
Phase 4RecruitingBerkeley Eye Center3202025-03-172026-09-30
Evaluation of a Monofocal Intraocular Lens
CT LUCIA 621P - Cataract
Phase 4CompletedCarl Zeiss Meditec AG442024-06-062026-07-22
Symfony vs Vivity in Dim Light
Symfony IOL, Vivity IOL - Cataract
Phase 4CompletedCarolina Eyecare Physicians, LLC642023-12-012025-02-14
The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammatory Markers
Omega-3, Trehalose, Zocular Eyelid System Treatment - Dry Eye, Dry Eye Syndromes
Phase 4UnknownUptown Eye Specialists682023-09-012023-08-14
Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery
Bromfenac, Moxifloxacin 0.5% ophthalmic solution, Dexamethasone phosphate 0.1% - Cataract, Cystoid Macular Edema After Phacoemulsification
Phase 4CompletedInas Abd872023-05-012025-05-06
The Evaluation of Balanced Salt Solution During Cataract Surgery
BSS Plus, BSS - Fuchs Dystrophy, Cataract
Phase 4CompletedAdam Fedyk, MD, FACS262023-04-172025-07-03
A Study for Post op Inflammation After Cataract Surgery
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% - Cataract
Phase 4UnknownWyse Eyecare402023-01-302023-04-26
Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.
Dextenza 0.4Mg Ophthalmic Insert - Cataract
Phase 4CompletedIworks Laser and Vision Center802022-06-152023-08-23
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
Dropless Regimen, Standard Regimen - Cataract, Surgery
Phase 4RecruitingUniversity of California, San Francisco702022-05-312026-10-27
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Dexamethasone, Prednisolone Acetate Ophthalmic - Cataract
Phase 4TerminatedEyePoint Pharmaceuticals, Inc.172022-01-042026-10-05
The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1
Dexamethasone 0.4 MG [Dextenza] - Cataract
Phase 4CompletedGrene Vision Group232021-12-132023-07-06

Showing 20 of 161. Sign in to see all of them.

Narrower conditions

Cataract (159)  ·  Dry Eye Syndromes (9)  ·  Glaucoma (5)  ·  Inflammation (5)  ·  Macular Edema (5)  ·  Aphakia (4)  ·  Astigmatism (4)  ·  Pseudophakia (4)  ·  Glaucoma, Open-Angle (3)  ·  Capsule Opacification (2)  ·  Exfoliation Syndrome (2)  ·  Mydriasis (2)  ·  Presbyopia (2)  ·  Vision Disorders (2)

Broader conditions

Eye Diseases (160)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Lacrimal Apparatus Diseases (9)  ·  Retinal Diseases (8)  ·  Retinal Degeneration (7)  ·  Ocular Hypertension (6)  ·  Pathologic Processes (6)  ·  Refractive Errors (6)  ·  Signs and Symptoms (6)  ·  Macular Degeneration (5)  ·  Endocrine System Diseases (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Corneal Diseases (2)  ·  Diabetes Mellitus (2)

Interventions

prednisolone acetate (14)  ·  Calcium Dobesilate (12)  ·  Ophthalmic Solutions (10)  ·  bromfenac (9)  ·  Ketorolac (8)  ·  Moxifloxacin (8)  ·  Phacoemulsification (8)  ·  Cataract Extraction (7)  ·  Dexamethasone (7)  ·  nepafenac (7)  ·  Lenses, Intraocular (5)  ·  Epinephrine (3)  ·  Ketorolac Tromethamine (3)  ·  Levofloxacin (3)  ·  Methylprednisolone (3)

Sponsors

Alcon Research (23)  ·  Innovative Medical (13)  ·  Bausch & Lomb Incorporated (8)  ·  Carl Zeiss Meditec AG (4)  ·  Aurolab (3)  ·  Carolina Eyecare Physicians, LLC (3)  ·  Frank A. Bucci, Jr., M.D. (3)  ·  Hospital Hietzing (3)  ·  Hospital Oftalmologico de Brasilia (3)  ·  Indiana University (3)  ·  Technolas Perfect Vision GmbH (3)  ·  Berkeley Eye Center (2)  ·  Bp Consulting, Inc (2)  ·  Bucci Laser Vision Institute (2)  ·  Federal University of São Paulo (2)

Countries

United States (81)  ·  Germany (10)  ·  Brazil (8)  ·  India (8)  ·  Austria (7)  ·  Czechia (4)  ·  China (3)  ·  South Korea (3)  ·  Taiwan (3)  ·  United Kingdom (3)  ·  Canada (2)  ·  Egypt (2)  ·  Singapore (2)  ·  Spain (2)  ·  Argentina (1)

Top investigators

Louis B Cantor, MD (3)  ·  Eckart Bertelmann, MD, PhD (2)  ·  Frank A Bucci, Jr., MD (2)  ·  Frank A. Bucci, Jr., MD (2)  ·  Gabriele Brenger (2)  ·  Haripriya Aravind, MBBS, MS (2)  ·  Kerry D Solomon, MD (2)  ·  Matthias G Wirtitsch, MD (2)  ·  Nadja Karnik, MD (2)  ·  Patrick F Tzelikis, MD, PhD (2)  ·  Phillip J Buckhurst, PhD (2)  ·  Abayomi Ogundele, PharmD (1)  ·  Abhay R Vasavada, MS,FRCS (1)

Results publications

PMID 12231329, PMID 15030845, PMID 15232477, PMID 15313288, PMID 16286622, PMID 16863978, PMID 17276271, PMID 18165083, PMID 18211932, PMID 18291345, PMID 18599019, PMID 20216291, PMID 21187730, PMID 21704965, PMID 21940140, PMID 24339307, PMID 25385061, PMID 25880685, PMID 29669780, PMID 32818353, PMID 33086290, PMID 34383010, PMID 35067660, PMID 39127813, PMID 40146119, PMID 40977319

NIH funding

R01AG015812 (1)